Skip to main content

Table 1 MIC breakpoints stated by the Clinical and Laboratory Standards Institute (CLSI), American FDA, and European Committee on Antimicrobial Susceptibility Testing (EUCAST)

From: Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement

 

CLSI

FDA

EUCAST

Microorganism

S

I

R

S

I

R

S

I

R

Enterobacterales

< 4

8

> 16

< 4

8

> 16

< 2

--

> 2

P. aeruginosa

< 4

8

> 16

< 1

2

> 4

< 2

--

> 2

A. baumannii

< 4

8

> 16

< 1

2

> 4

NA

NA

NA

S. maltophilia

< 4

8

> 16

NA

NA

NA

NA

NA

NA

  1. Breakpoint CLSI published in June 2018; update expected in 2021. Breakpoint FDA updated till September 2020. Breakpoint EUCAST published in April 2020
  2. I intermediate, NA non-applicable, R resistant, S sensible, MIC minimum inhibitory concentration, CLSI Clinical and Laboratory Standards Institute, FDA Food and Drug Administration, EUCAST European Committee on Antimicrobial Susceptibility Testing